Recursion Pharmaceuticals, Inc. (RXRX)
4.12
+0.05
(+1.23%)
USD |
NASDAQ |
Oct 02, 16:00
4.12
0.00 (0.00%)
Pre-Market: 20:00
Recursion Pharmaceuticals Enterprise Value : 1.716B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.716B |
| October 01, 2026 | 1.689B |
| September 30, 2026 | 1.721B |
| September 29, 2026 | 1.668B |
| September 28, 2026 | 1.492B |
| September 25, 2026 | 1.513B |
| September 24, 2026 | 1.593B |
| September 23, 2026 | 1.492B |
| September 22, 2026 | 1.679B |
| September 21, 2026 | 1.636B |
| September 18, 2026 | 1.561B |
| September 17, 2026 | 1.406B |
| September 16, 2026 | 1.219B |
| September 15, 2026 | 1.246B |
| September 14, 2026 | 1.337B |
| September 11, 2026 | 1.225B |
| September 10, 2026 | 1.203B |
| September 09, 2026 | 1.233B |
| September 08, 2026 | 1.353B |
| September 04, 2026 | 1.454B |
| September 03, 2026 | 1.353B |
| September 02, 2026 | 1.321B |
| September 01, 2026 | 1.294B |
| August 31, 2026 | 1.332B |
| August 28, 2026 | 1.300B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.353B |
| August 26, 2026 | 1.380B |
| August 25, 2026 | 1.417B |
| August 24, 2026 | 1.251B |
| August 21, 2026 | 1.385B |
| August 20, 2026 | 1.300B |
| August 19, 2026 | 1.385B |
| August 18, 2026 | 1.166B |
| August 17, 2026 | 1.177B |
| August 14, 2026 | 1.203B |
| August 13, 2026 | 1.284B |
| August 12, 2026 | 1.273B |
| August 11, 2026 | 1.305B |
| August 10, 2026 | 1.273B |
| August 07, 2026 | 1.235B |
| August 06, 2026 | 1.214B |
| August 05, 2026 | 1.209B |
| August 04, 2026 | 1.284B |
| August 03, 2026 | 1.214B |
| July 31, 2026 | 1.118B |
| July 30, 2026 | 1.139B |
| July 29, 2026 | 1.102B |
| July 28, 2026 | 1.145B |
| July 27, 2026 | 1.123B |
| July 24, 2026 | 1.097B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Editas Medicine, Inc. | 261.86M |
| Amgen, Inc. | 261.20B |
| Halozyme Therapeutics, Inc. | 14.44B |
| Novavax, Inc. | 1.302B |
| AVITA Medical, Inc. | 430.73M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -131.00M |
| Revenue (Quarterly) | 7.67M |
| Total Expenses (Quarterly) | 138.68M |
| EPS Diluted (Quarterly) | -0.246 |
| Gross Profit Margin (Quarterly) | -202.4% |
| Profit Margin (Quarterly) | -1.71K% |
| Earnings Yield | -25.15% |
| Normalized Earnings Yield | -25.15 |